Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor

Not yet recruiting

2

Start Date 11/01/2021

Age of Trial (yrs) 1.6

Gleevec-resistant

KIT/PDGFRA inhibitor + MEK inhibitor

Block KIT + Block related tumor signal paths

Specifically GIST and only GIST

DCC-2618-01-008

Deciphera Pharmaceuticals LLC

Study Director 785-830-2100 clinicaltrials@deciphera.com

Oral

Exclusion Criteria:

Received prior anticancer therapy within 14 days or 5× the half-life whichever is longer) prior to the first dose.
Ongoing or prior participation in the DCC-2618-03-002 study.
Prior therapy with ripretinib.
Prior therapy with MEK inhibitor.
History of certain ocular disorders.
History of clinically significant hepatobiliary disease.
Known active central nervous system metastases.
History or presence of clinically relevant cardiovascular abnormalities.
Systemic arterial or venous thrombotic or embolic events within 6 months of first dose.
History of acute or chronic pancreatitis
History of chronic inflammatory bowel disease or Crohn's disease requiring intervention within 12 months of first dose.

Gastrointestinal abnormalities including but not limited to:
inability to take oral medication,
malabsorption syndromes